MedCap ABOMXSTO: MCAP

MCAP: Q3 2024 delivered double-digit sales growth, led by Assistive Tech and MedTech strength

· Issued by MedCap AB

Q3 2024 saw 13% sales growth and strong results in Assistive Tech and MedTech, while Specialty Pharma declined due to UK price pressure. Acquisitions and a robust balance sheet support continued M&A activity.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

MedCap AB on 6ix

Story so far

Earlier from MedCap

Later from MedCap

All MedCap news releases